Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
Conditions
Interventions
Nemvaleukin Alfa
Pembrolizumab
Locations
7
United States
Mural Oncology Investigational Site
Miami, Florida, United States
Mural Oncology Investigational Site
Atlanta, Georgia, United States
Mural Oncology Investigational Site
Minneapolis, Minnesota, United States
Mural Oncology Investigational Site
New York, New York, United States
Mural Oncology Investigational Site
New York, New York, United States
Mural Oncology Investigational Site
Cleveland, Ohio, United States
Start Date
February 5, 2020
Primary Completion Date
October 8, 2021
Completion Date
January 7, 2022
Last Updated
October 16, 2024
NCT06385080
NCT06487403
NCT06242470
NCT05553782
NCT05317000
NCT04528420
Lead Sponsor
Mural Oncology, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions